Nifenova (Nifedipine)

Nifenova belongs to the calcium channel blocker class and is indicated for conditions involving elevated vascular tone and myocardial oxygen demand.

• Hypertension: helps lower systolic and diastolic blood pressure by relaxing arterial smooth muscle.
• Angina pectoris: reduces frequency of chest pain episodes by improving coronary blood flow.
• Chronic stable angina: decreases myocardial oxygen consumption during exertion.

• Nifedipine selectively blocks L‑type calcium channels in vascular smooth muscle and cardiac myocytes. This inhibition reduces calcium influx, causing vasodilation of peripheral arteries, lowering systemic vascular resistance, and decreasing myocardial oxygen demand, which together help control blood pressure and relieve anginal pain.

Nifenova may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness: related to blood pressure reduction.
• Tachycardia: increased heart rate, especially after the first dose.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Myocardial infarction: rare but possible in patients with pre‑existing coronary disease.
• Liver dysfunction: abnormal liver enzymes or hepatitis.
• Allergic reactions: rash, itching, or anaphylaxis.
• Arrhythmias: abnormal heart rhythms, particularly in patients with conduction disorders.
• Heart failure exacerbation: worsening of existing heart failure symptoms.

Before prescribing Nifenova, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Discontinuation: avoid abrupt stopping; taper if clinically indicated.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Heart failure: assess severity; monitor for fluid retention.
• Concomitant grapefruit products: avoid as they can increase nifedipine levels.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nifenova can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic levels of nifedipine.
• Other antihypertensives (e.g., beta‑blockers, ACE inhibitors): additive blood pressure lowering.
• Simvastatin high doses: increased risk of myopathy.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

• Diuretics: may enhance orthostatic hypotension.
• Digoxin: monitor serum levels for potential increase.